Development Agreements in the Biotechnology Industry

596 Contracts & Agreements

Browse by Company

ACADIA PHARMACEUTICALS INC (5 contracts)
Achaogen, Inc. (4)
Acorda Therapeutics (2)
Adaptimmune Therapeutics PLC (3)
ADURO BIOTECH, INC. (1)
Aeglea BioTherapeutics, Inc. (1)
AGENUS INC (3)
ALBIREO PHARMA, INC. (1)
Alkermes plc. (1)
Allakos Inc. (1)
Alliqua BioMedical, Inc. (1)
ALNYLAM PHARMACEUTICALS, INC. (1)
Altimmune, Inc. (5)
ALX ONCOLOGY HOLDINGS INC (2)
AMARILLO BIOSCIENCES INC (2)
AMARIN CORP PLC (2)
AmpliPhi Biosciences Corp (1)
Anixa Biosciences Inc (1)
Apellis Pharmaceuticals, Inc. (2)
Arbutus Biopharma Corp (1)
ARCA biopharma, Inc. (4)
Arcturus Therapeutics Holdings Inc. (4)
Atara Biotherapeutics, Inc. (5)
Athenex, Inc. (5)
ATHERSYS, INC (47)
Avita Therapeutics, Inc. (2)
BIO-PATH HOLDINGS INC (1)
bioAffinity Technologies, Inc. (1)
BIOCRYST PHARMACEUTICALS INC (17)
BIOMARIN PHARMACEUTICAL INC (1)
BioNexus Gene Lab Coporation (1)
BioRestorative Therapies, Inc. (1)
BIOTIME INC (4)
Bone Biologics Corp (1)
BullFrog AI Holdings, Inc. (1)
CALADRIUS BIOSCIENCES, INC. (1)
CANCER GENETICS, INC (1)
Capstone Therapeutics Corp. (6)
CASI Pharmaceuticals, Inc. (4)
CATALYST BIOSCIENCES, INC. (6)
Cell Source, Inc. (4)
Celldex Therapeutics, Inc. (1)
Celsion CORP (4)
Chelsea Worldwide Inc. (1)
ChemoCentryx, Inc. (9)
CHIMERIX INC (28)
Conatus Pharmaceuticals Inc. (1)
CONCERT PHARMACEUTICALS, INC. (1)
CONSTELLATION PHARMACEUTICALS INC (1)
CONTRAFECT Corp (2)
Corvus Pharmaceuticals, Inc. (1)
CRISPR Therapeutics AG (2)
Curative Biotechnology Inc (3)
Cyclerion Therapeutics, Inc. (1)
CytoDyn Inc. (1)
Cytokinetics, Incorporated (13)
CYTORI THERAPEUTICS, INC. (1)
DiaMedica Therapeutics Inc. (2)
Dicerna Pharmaceuticals Inc (1)
Digital Development Partners, Inc. (4)
DYADIC INTERNATIONAL INC (1)
Dynamics Special Purpose Corp. (1)
Eagle Pharmaceuticals, Inc. (3)
Edge Therapeutics, Inc. (2)
Eiger BioPharmaceuticals, Inc. (3)
Emerald Bioscience, Inc. (2)
Emergent BioSolutions Inc. (22)
Entasis Therapeutics Holdings Inc. (1)
Evelo Biosciences, Inc. (1)
EVOLUTIONARY GENOMICS, INC. (1)
Exelixis (9)
FIBROGEN INC (17)
FS Development Corp. (5)
FS Development Corp. II (5)
Fusion Pharmaceuticals Inc. (2)
Gritstone Oncology, Inc. (2)
GTX INC (27)
Harpoon Therapeutics, Inc. (4)
HISTOGENICS CORP (2)
HUMANIGEN, INC (1)
iBio, Inc. (2)
IDERA PHARMACEUTICALS, INC. (1)
Immune Therapeutics, Inc. (1)
ImmunoCellular Therapeutics, Ltd. (1)
IMMUNOGEN INC (1)
Inhibikase Therapeutics, Inc. (2)
Inmune Bio, Inc. (1)
Intec Pharma Ltd. (1)
INTERCEPT PHARMACEUTICALS, INC. (4)
IONIS PHARMACEUTICALS INC (2)
IOVANCE BIOTHERAPEUTICS, INC. (3)
Isoray, Inc. (2)
Kindred Biosciences, Inc. (2)
LEXICON PHARMACEUTICALS, INC. (1)
LianBio (3)
Ligand Pharmaceuticals Incorporated (4)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (1)
LONGEVERON LLC (2)
MADRIGAL PHARMACEUTICALS, INC. (1)
Magenta Therapeutics, Inc. (2)
MATEON THERAPEUTICS INC (2)
Matinas BioPharma Holdings, Inc. (1)
MEDICINOVA INC (1)
MiMedx Group, Inc. (1)
Moderna, Inc. (6)
Moleculin Biotech, Inc. (4)
NEUROBIOLOGICAL TECHNOLOGIES INC (1)
NEUROCRINE BIOSCIENCES INC (1)
NEWLINK GENETICS CORP (27)
NORTHWEST BIOTHERAPEUTICS INC (1)
NOVAVAX INC (3)
Omega Therapeutics, Inc. (2)
ONCOSEC MEDICAL Inc (7)
Orchard Therapeutics plc (1)
Orgenesis Inc. (1)
Passage BIO, Inc. (2)
PLURISTEM THERAPEUTICS INC (16)
PORTOLA PHARMACEUTICALS INC (1)
PROTEON THERAPEUTICS INC (1)
PROTEOSTASIS THERAPEUTICS, INC. (1)
Prothena Corp plc (1)
Radius Health, Inc. (5)
Regeneron Pharmaceuticals (4)
REGENXBIO Inc. (2)
Regulus Therapeutics Inc. (1)
Revolution Medicines, Inc. (1)
RHYTHM PHARMACEUTICALS, INC. (4)
RITTER PHARMACEUTICALS INC (1)
Sana Biotechnology, Inc. (1)
SANGAMO THERAPEUTICS, INC (2)
Sarepta Therapeutics, Inc. (1)
Savara Inc (5)
SEATTLE GENETICS INC (17)
SELLAS Life Sciences Group, Inc. (2)
Social Capital Suvretta Holdings Corp. III (1)
SOPHIRIS BIO INC. (3)
Spectrum Pharmaceuticals, Inc. (3)
T2 Biosystems, Inc. (10)
TENAX THERAPEUTICS, INC. (1)
Tocagen Inc (1)
Tonix Pharmaceuticals Holding Corp. (1)
Tracon Pharmaceuticals, Inc. (7)
TREVENA INC (2)
Trovagene, Inc. (2)
U.S. Stem Cell, Inc. (1)
Ultragenyx Pharmaceutical Inc. (2)
Unicycive Therapeutics, Inc. (1)
VACCINEX, INC. (1)
Vaxcyte, Inc. (8)
VERACYTE, INC. (1)
Vertex Pharmaceuticals Inc (10)
Verve Therapeutics, Inc. (1)
VICAL INC (1)
Viela Bio, Inc. (1)
Vir Biotechnology, Inc. (3)
VistaGen Therapeutics, Inc. (1)
VITRO DIAGNOSTICS INC (3)
WINDTREE THERAPEUTICS INC (3)
Xencor Inc (3)
Xenetic Biosciences, Inc. (1)
XOMA Corp (3)
ZIOPHARM ONCOLOGY INC (12)

Recent Contracts

Amendment No. 1 to Contract between the Company and the Biomedical Advanced Research and Development Authority, effective as of November 20, 2023 (Gritstone Oncology, Inc., Filed With SEC on March 5, 2024)
Amended and Restated Development Services and Clinical Supply Agreement, dated November 9, 2023, by and between the Registrant and Catalent Maryland, Inc (Passage BIO, Inc., Filed With SEC on March 4, 2024)
Amendment No. 2 to Development Funding and Royalties Agreement, dated as of November 29, 2023, by and between the Company and Palvella Therapeutics, Inc (Ligand Pharmaceuticals Incorporated, Filed With SEC on February 29, 2024)
Amendment No. 1 to Development Funding and Royalties Agreement, dated as of May 22, 2020, by and between the Company and Palvella Therapeutics, Inc (Ligand Pharmaceuticals Incorporated, Filed With SEC on February 29, 2024)
Master Services Agreement for Drug Product Development and Manufacturing between Registrant and Lonza Ltd., dated March 22, 2022, as amended (Vaxcyte, Inc., Filed With SEC on February 27, 2024)
Amendment No. 1 to Amended and Restated Joint Development and Commercialization Agreement, dated December 23, 3023, between Vertex Pharmaceuticals Incorporated, Vertex... (Vertex Pharmaceuticals Inc, Filed With SEC on February 15, 2024)
English Translation of Addendum to the Product Development Agreement, dated on January 9, 2024 (AMARILLO BIOSCIENCES INC, Filed With SEC on January 12, 2024)
English Translation of Product Development Agreement, dated on August 1, 2021 (AMARILLO BIOSCIENCES INC, Filed With SEC on January 12, 2024)
Amendment No. 1 to the Amended and Restated Joint Development and Commercialization Agreement, dated December 12, 2023, by and between, on the one hand, Vertex Pharmaceuticals... (CRISPR Therapeutics AG, Filed With SEC on December 13, 2023)
Development and Manufacturing Services Agreement between Senti Biosciences, Inc. and GeneFab, LLC, dated August 7, 2023 (Dynamics Special Purpose Corp., Filed With SEC on November 14, 2023)
Supplemental Agreement for nHCM, dated as of August 11, 2023, by and between MyoKardia, Inc., LianBio, LianBio Licensing, LLC, Lian Cardiovascular Limited, and Shanghai LianBio... (LianBio, Filed With SEC on November 13, 2023)
Contract between the Company and the Biomedical Advanced Research and Development Authority, dated September 27, 2023 (Gritstone Oncology, Inc., Filed With SEC on November 8, 2023)
Amendment No. 1 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration... (Vir Biotechnology, Inc., Filed With SEC on November 3, 2023)
Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic... (Vir Biotechnology, Inc., Filed With SEC on November 3, 2023)
Development and Supplemental Agreement between Elan Pharma International Limited and Acorda Therapeutics, Inc. dated January 14, 2011 (Alkermes plc., Filed With SEC on October 25, 2023)
Commercial Agreement by and between the Company and the Lieber Institute for Brain Development dated October 13, 2023 (BullFrog AI Holdings, Inc., Filed With SEC on October 20, 2023)
Development Agreement between Cardiff Oncology, Inc. and Pfizer, Inc. dated June 30, 2023 (Trovagene, Inc., Filed With SEC on August 9, 2023)
Amendment of Solicitation/Modification of Contract, dated as of May 1, 2023 by and between the Company and Biomedical Advanced Research and Development Authority of the U.S.... (T2 Biosystems, Inc., Filed With SEC on May 22, 2023)
Commercialization Agreement, dated as of December 16, 2022, by and among LianBio Development (HK) Limited, LianBio Respiratory Limited, ReViral Ltd. and Pfizer Inc (LianBio, Filed With SEC on March 28, 2023)
Amendment Agreement No. 8 made and effective as of December 19, 2022 by and between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Adaptimmune Therapeutics PLC, Filed With SEC on December 20, 2022)
Amendment to Development and Licensing Agreement, by and between the Company and Robert One, LLC, dated December 9, 2022 (Eagle Pharmaceuticals, Inc., Filed With SEC on December 14, 2022)
Therapeutic Development Award Agreement, by and between Arrevus, Inc. and Cystic Fibrosis Foundation, dated December 13, 2021 (IDERA PHARMACEUTICALS, INC., Filed With SEC on November 14, 2022)
Amendment of Solicitation/Modification of Contract, dated as of September 29, 2022 by and between the Company and Biomedical Advanced Research and Development Authority of the... (T2 Biosystems, Inc., Filed With SEC on November 14, 2022)
Amendment of Solicitation/Modification of Contract between the Biomedical Advanced Research and Development Authority and ContraFect Corporation, dated August 24, 2022 (CONTRAFECT Corp, Filed With SEC on November 14, 2022)
Amendment of Solicitation/Modification of Contract dated September 29, 2015 between the registrant and the U.S Department of Health and Human Services Biomedical Advanced Research... (Avita Therapeutics, Inc., Filed With SEC on November 10, 2022)
Amendment of Solicitation/Modification of Contract dated September 29, 2015 between the registrant and the U.S Department of Health and Human Services Biomedical Advanced Research... (Avita Therapeutics, Inc., Filed With SEC on November 10, 2022)
Portfolio Development Advisor Agreement dated September 6, 2022 between KEWAT, LLC and Moleculin Biotech, Inc (Moleculin Biotech, Inc., Filed With SEC on November 10, 2022)
Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated October 21, 2016, as amended (Vaxcyte, Inc., Filed With SEC on November 7, 2022)
Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Curative Biotechnology Inc, Filed With SEC on November 7, 2022)
Joint Development Agreement, dated May 15, 2018, by and between the Registrant and Jack Zamora (VITRO DIAGNOSTICS INC, Filed With SEC on September 9, 2022)
Amendment of Solicitation/Modification of Contract, dated as of July 26, 2022 by and between the Company and Biomedical Advanced Research and Development Authority of the U.S.... (T2 Biosystems, Inc., Filed With SEC on August 16, 2022)
Fourth Amendment to the Cooperative Research and Development Agreement, dated June 24, 2022, by and between the National Cancer Institute and the Registrant (ZIOPHARM ONCOLOGY INC, Filed With SEC on August 15, 2022)
Master Services Agreement, dated May 1, 2019, by and between PPD Development, LP and ProKidney (formerly RegenMed (Cayman) Ltd.) (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Statement of Work No. 1 to the Contract Development Manufacture Agreement (NOVAVAX INC, Filed With SEC on August 9, 2022)
Amendment No. 1 to the Contract Development Manufacture Agreement (NOVAVAX INC, Filed With SEC on August 9, 2022)
Contract Development Manufacture Agreement (NOVAVAX INC, Filed With SEC on August 9, 2022)
Master Services Agreement for Drug Product Development and Manufacturing between the Registrant and Lonza Ltd., dated March 22, 2022, as amended (Vaxcyte, Inc., Filed With SEC on August 8, 2022)
Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated October 21, 2016, as amended (Vaxcyte, Inc., Filed With SEC on August 8, 2022)
Amendment No. 13 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of March 23, 2022 (Moderna, Inc., Filed With SEC on August 3, 2022)
Thirteenth Amendment to Development and Supply Agreement, effective May 12, 2022 between Seagen Inc. (f/k/a Seattle Genetics, Inc.) and AbbVie Inc. (formerly part of Abbott... (SEATTLE GENETICS INC, Filed With SEC on July 28, 2022)